Annals of Allergy Asthma & Immunology最新文献

{"title":"Highly accurate, noninvasive early identification of infants with a filaggrin loss-of-function mutation by in vivo Raman spectroscopy, followed from birth to 12 months","authors":"Gerwin J. Puppels PhD ,&nbsp;Jonathan O'B. Hourihane MD ,&nbsp;Claudio Nico PhD ,&nbsp;Carol Ni Chaoimh PhD ,&nbsp;Colin Wong BSc ,&nbsp;John E. Common PhD ,&nbsp;Peter J. Caspers PhD ,&nbsp;Alan D. Irvine MD, DSc","doi":"10.1016/j.anai.2025.01.010","DOIUrl":"10.1016/j.anai.2025.01.010","url":null,"abstract":"<div><h3>Background</h3><div>Loss-of-function <em>FLG</em> mutation (<em>FLGmut</em>) carriers are at an increased risk of developing atopic dermatitis (AD), characterized by earlier onset and more severe disease. AD is driven by a complex interplay between skin barrier function, T_H2 and T_H2-dominant immune dysregulation, and dysbiosis. Results from the Short-Term Topical Application for Prevention of Atopic Dermatitis study suggest 2 early initiating AD pathogenetic pathways: an <em>FLGmut</em>-related skin barrier deficiency pathway and an immune function-related inflammatory pathway. The Short-Term Topical Application for Prevention of Atopic Dermatitis study suggested that early preventative intervention with specialized emollients for barrier function augmentation may benefit newborns with <em>FLGmut</em>. This requires early identification of <em>FLGmut</em> carriers, for which noninvasive Raman spectroscopic determination of natural moisturizing factor (NMF) levels in the stratum corneum of the thenar eminence provides a surrogate marker.</div></div><div><h3>Objective</h3><div>To identify strategies for early identification of infants with <em>FLGmut</em>.</div></div><div><h3>Methods</h3><div><em>FLG</em> sequencing was performed on 253 infants, and NMF concentrations were measured in the stratum corneum of the palmar eminence (pSC-NMF) using noninvasive Raman spectroscopy at 6 time points after birth. Furthermore, the pSC-NMF concentrations were obtained from both parents of 150 infants.</div></div><div><h3>Results</h3><div>Babies are born with little to no NMF. In the first days after birth, NMF levels rapidly increase and 65% of newborns with <em>FLG</em> wild type already reach pSC-NMF concentrations, which excludes them as <em>FLGmut</em> carriers with high specificity. At 2 weeks of age, <em>FLGmut</em> carriers could be distinguished from newborns with <em>FLG</em> wild type with high sensitivity (97%) and specificity (97%). In addition, parent pSC-NMF concentrations offer the possibility to exclude their newborn as <em>FLGmut</em> carriers with high specificity.</div></div><div><h3>Conclusion</h3><div>Noninvasive Raman spectroscopy enables the accurate early identification of infants with <em>FLGmut</em>.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 457-464"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desensitization with telemedicine: A novel protocol using remote monitoring for oral immunotherapy for alpha-gal syndrome","authors":"Albert G. Wu MD ,&nbsp;Malina C. Patel MD ,&nbsp;Manish Ramesh MD, PhD","doi":"10.1016/j.anai.2025.01.001","DOIUrl":"10.1016/j.anai.2025.01.001","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 488-489"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The combination of allergen immunotherapy and biologics for inhalant allergies: Exploring the synergy","authors":"Bianca Olivieri MD ,&nbsp;Fatma Esra Günaydın MD ,&nbsp;Jonathan Corren MD ,&nbsp;Gianenrico Senna MD ,&nbsp;Stephen R. Durham MD","doi":"10.1016/j.anai.2024.06.016","DOIUrl":"10.1016/j.anai.2024.06.016","url":null,"abstract":"<div><div><span>The development of monoclonal antibodies that selectively target IgE and type 2 immunity has opened new possibilities in the treatment of allergies. Although they have been used mainly as single therapies found to have efficacy in the management of asthma and other T2-mediated diseases, there is a growing interest in using these monoclonal antibodies in combination with </span>allergen immunotherapy<span> (AIT). AIT has transformed the treatment of allergic diseases by aiming to modify the underlying immune response to allergens rather than just providing temporary symptom relief. Despite the proven efficacy and safety of AIT, unmet needs call for further research and innovation. Combination strategies involving biologics and AIT exhibit potential in improving short-term efficacy, reducing adverse events, and increasing immunologic tolerance. Anti-IgE emerges as the most promising therapeutic strategy, not only enhancing AIT's safety and tolerability but also providing additional evidence of efficacy compared with AIT alone. Anti–interleukin-4 receptor offers a reduction in adverse effects and an improved immunologic profile when combined with AIT; however, its impact on short-term efficacy seems limited. The combination of cat dander<span> subcutaneous immunotherapy with anti-thymic stromal lymphopoietin was synergistic with enhanced efficacy and altered immune responses that persisted for 1 year after discontinuation compared with AIT alone. Long-term studies are needed to evaluate the sustained benefits and safety profiles of combination strategies.</span></span></div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 385-395"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141428174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria","authors":"David M. Lang MD ,&nbsp;Javed Sheikh MD ,&nbsp;Shyam Joshi MD ,&nbsp;Jonathan A. Bernstein MD","doi":"10.1016/j.anai.2024.10.026","DOIUrl":"10.1016/j.anai.2024.10.026","url":null,"abstract":"<div><div>Chronic spontaneous urticaria (CSU) is an inflammatory disorder that manifests with hives, angioedema, or both and lasts more than or equal to 6 weeks. Although certain elements of CSU pathogenesis are well defined, others remain unclear. We discuss our current understanding of the underlying CSU endotypes, distinct clinical phenotypes, and predictive biomarkers. It is increasingly recognized that CSU comprises a spectrum of different underlying pathogenic mechanisms and distinct clinical presentations. Broadly, 2 endotypes that drive CSU pathogenesis have been identified, namely type I (autoallergic) and type IIb (autoimmune). However, a subpopulation shows evidence of both types, and some patients show evidence of neither. Multiple identified biomarkers have been associated with these endotypes or with disease features, such as CSU severity and duration. There is a lack of connectivity among the identified biomarkers, genetic risk loci, phenotypes, and corresponding endotypes, and each of these is frequently considered independently of the others. These identifiable features also have been associated with response, or lack thereof, to available therapies. Future investigations should optimize the endotyping of CSU using point-of-care, noninvasive, accessible biomarkers and assess the differences in response to therapy. With multiple treatments in late-stage development, establishing clearly defined CSU endotypes will facilitate future treatment decision-making and tailored treatment approaches and will inform optimal trial design.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 408-417.e3"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote oral immunotherapy updosing","authors":"Richard L. Wasserman MD, PhD","doi":"10.1016/j.anai.2025.01.011","DOIUrl":"10.1016/j.anai.2025.01.011","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 374-375"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors’ response","authors":"Timothy Craig DO ,&nbsp;Raffi Tachdjian MD ,&nbsp;Jonathan A. Bernstein MD ,&nbsp;John Anderson MD ,&nbsp;Christina Nurse PhD ,&nbsp;Maureen Watt MSc ,&nbsp;Ming Yu MD ,&nbsp;Salomé Juethner MSN","doi":"10.1016/j.anai.2025.02.003","DOIUrl":"10.1016/j.anai.2025.02.003","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 493-494"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S1081-1206(25)00111-5","DOIUrl":"10.1016/S1081-1206(25)00111-5","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Page A4"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Future of allergy and immunology","authors":"Polat Goktas PhD ,&nbsp;Ebru Damadoglu MD","doi":"10.1016/j.anai.2024.10.019","DOIUrl":"10.1016/j.anai.2024.10.019","url":null,"abstract":"<div><div>Artificial intelligence (AI) is reshaping allergy and immunology by integrating cutting-edge technology to enhance patient outcomes and redefine clinical practices and research. This review evaluates AI's evolving role, emphasizing its impact on diagnostic accuracy, personalized treatments, and innovative research methodologies. AI has advanced diagnostic tools, such as models predicting allergen sensitivity, and enhanced immunotherapy strategies. Its ability to process extensive data sets has enabled deeper understanding of allergic diseases and immune system responses, leading to more accurate, effective, and tailored treatments. Furthermore, AI is facilitating personalized care through AI-driven allergen mapping, automated patient monitoring, and targeted immunotherapy. The integration of AI into clinical practice promises a future in which allergy and immunology are characterized by precisely customized health care solutions. This review adheres to Preferred Reporting Items for Systematic reviews and Meta-Analyses flowchart, with a comprehensive analysis of databases, including Scopus, Web of Science, PubMed, and preprint platforms using keywords related to AI and allergy and immunology. From an initial pool of 192 studies, 20 documents were selected based on inclusion criteria. Our findings highlight how AI is transforming allergy and immunology by enhancing patient care, research methodologies, and clinical innovation, offering a glimpse into the near future of technology-driven health care in these fields.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 396-407.e2"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The combination of allergen immunotherapy and biologics for inhalant allergies","authors":"Christopher A. Coop MD,&nbsp;Brittanie I. Neaves MD","doi":"10.1016/j.anai.2024.06.028","DOIUrl":"10.1016/j.anai.2024.06.028","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Page 371"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impulse oscillometry","authors":"Ourania S. Kotsiou PhD ,&nbsp;Paraskevi Kirgou PhD ,&nbsp;Dimitra Siachpazidou PhD ,&nbsp;Konstantinos Bartziokas PhD ,&nbsp;Konstantinos Tourlakopoulos MD ,&nbsp;Foteini Malli PhD ,&nbsp;Maria Pinaka MD ,&nbsp;Zoe Daniil PhD ,&nbsp;Konstantinos I. Gourgoulianis PhD","doi":"10.1016/j.anai.2024.12.018","DOIUrl":"10.1016/j.anai.2024.12.018","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Page 490"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}